Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 14/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4005554 | 0.94 | GSK3B (0.45) | GSK3BCYP1A2CYP2D6 | |
| SCHEMBL4004219 | 0.89 | GSK3B (0.44) | GSK3BMAOBADORA2ACYP1A2CYP2D6 | |
| SCHEMBL4006674 | 0.88 | ADORA2A (0.43) | GSK3BADORA2ACYP1A2CYP2D6 | |
| SCHEMBL4001235 | 0.86 | GSK3B (0.55) | GSK3BADORA2AALDH1A1MAPK1CYP1A2 | |
| SCHEMBL4005923 | 0.86 | MAOB (0.49) | GSK3BMAOBADORA2ACYP2D6 | |
| SCHEMBL3998733 | 0.84 | GSK3B (0.43) | GSK3BCYP1A2CYP2D6 | |
| SCHEMBL4862247 | 0.84 | GSK3B (0.44) | GSK3BCYP1A2CYP2D6 | |
| SCHEMBL4873826 | 0.84 | GSK3B (0.42) | GSK3BCYP1A2CYP2D6 | |
| SCHEMBL3999502 | 0.84 | GSK3B (0.46) | GSK3BCYP1A2CYP2D6 | |
| SCHEMBL3998481 | 0.83 | DRD2 (0.44) | GSK3BCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7566720-B2 | 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1,2-a] pyrimidin-5(1H)one derivatives | SANOFI-AVENTIS (FR) | 2009-07-28 | — | — | US | claimed |
| US-20080027078-A1 | 2-PYRIDINYL-6,7,8,9-TETRAHYDROPYRIMIDO[1,2-a] PYRIMIDIN-4-ONE AND 7-PYRIDINYL-2,3-DIHYDROIMIDAZO[1,2-a] PYRIMIDIN-5(1H)ONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2008-01-31 | — | — | US | claimed |
| US-20060014762-A1 | 2-Pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-A]pyrimidin-4-one and 7-pyridinyl-2,3-dihydoimidazo[1,2-A]pyrimidin-5(1H)one derivatives | SANOFI-AVENTIS (FR) | 2006-01-19 | — | — | US | claimed |
| US-6974819-B2 | 2-pyridinyl-6,7,8,9-tetrahydropyrimido{1,2-a}pyrimidin-4-one and 7-pyridinyl-2,3-dihydoimidazo{1,2-a}pyrimidin-5(1H)one derivatives | SANOFI-AVENTIS (FR) | 2005-12-13 | — | — | US | claimed |
| EP-1315731-B1 | 2-PYRIDINYL-6,7,8,9-TETRAHYDROPYRIMIDO[1,2-A]PYRIMIDIN-4-ONE AND 7-PYRIDINYL-2,3-DIHYDROIMIDAZO[1,2-A]PYRIMIDIN-5(1H)ONE DERIVATIVES | SANOFI SYNTHELABO (FR) | 2004-06-16 | — | — | EP | claimed |
| US-20040087598-A1 | 2-pyridinyl-6,7,8,9-tetrahydropyrimido{1,2-a}pyrimidin-4-one and 7-pyridinyl-1,3-dihydoimidazo{1,2-a}pyrimidin-5(1h)one derivatives | SANOFI (FR) | 2004-05-06 | — | — | US | claimed |
| EP-1315731-A1 | 2-PYRIDINYL-6,7,8,9-TETRAHYDROPYRIMIDO[1,2-A]PYRIMIDIN-4-ONE AND 7-PYRIDINYL-2,3-DIHYDROIMIDAZO[1,2-A]PYRIMIDIN-5(1H)ONE DERIVATIVES | SANOFI-SYNTHELABO (FR) | 2003-06-04 | — | — | EP | claimed |
| WO-2002018386-A1 | 2-PYRIDINYL-6,7,8,9-TETRAHYDROPYRIMIDO[1,2-a]PYRIMIDIN-4-ONE AND 7-PYRIDINYL-2,3-DIHYDROIMIDAZO[1,2-a]PYRIMIDIN-5(1H)ONE DERIVATI VES | SANOFI-SYNTHELABO (FR) | 2002-03-07 | — | — | WO | claimed |
| EP-1184383-A1 | 9-[Alkyl], 9-[(heteroaryl)alkyl] and 9-[(aryl)alkyl]-2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one derivatives | SANOFI-SYNTHELABO (FR) | 2002-03-06 | — | — | EP | claimed |
| US-7566720-B2 | 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1,2-a] pyrimidin-5(1H)one derivatives | SANOFI-AVENTIS (FR) | 2009-07-28 | — | — | US | disclosed |
| US-20080027078-A1 | 2-PYRIDINYL-6,7,8,9-TETRAHYDROPYRIMIDO[1,2-a] PYRIMIDIN-4-ONE AND 7-PYRIDINYL-2,3-DIHYDROIMIDAZO[1,2-a] PYRIMIDIN-5(1H)ONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2008-01-31 | — | — | US | disclosed |
| US-20060014762-A1 | 2-Pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-A]pyrimidin-4-one and 7-pyridinyl-2,3-dihydoimidazo[1,2-A]pyrimidin-5(1H)one derivatives | SANOFI-AVENTIS (FR) | 2006-01-19 | — | — | US | disclosed |
| US-6974819-B2 | 2-pyridinyl-6,7,8,9-tetrahydropyrimido{1,2-a}pyrimidin-4-one and 7-pyridinyl-2,3-dihydoimidazo{1,2-a}pyrimidin-5(1H)one derivatives | SANOFI-AVENTIS (FR) | 2005-12-13 | — | — | US | disclosed |
| EP-1315731-B1 | 2-PYRIDINYL-6,7,8,9-TETRAHYDROPYRIMIDO[1,2-A]PYRIMIDIN-4-ONE AND 7-PYRIDINYL-2,3-DIHYDROIMIDAZO[1,2-A]PYRIMIDIN-5(1H)ONE DERIVATIVES | SANOFI SYNTHELABO (FR) | 2004-06-16 | — | — | EP | disclosed |
| US-20040087598-A1 | 2-pyridinyl-6,7,8,9-tetrahydropyrimido{1,2-a}pyrimidin-4-one and 7-pyridinyl-1,3-dihydoimidazo{1,2-a}pyrimidin-5(1h)one derivatives | SANOFI (FR) | 2004-05-06 | — | — | US | disclosed |
| EP-1315731-A1 | 2-PYRIDINYL-6,7,8,9-TETRAHYDROPYRIMIDO[1,2-A]PYRIMIDIN-4-ONE AND 7-PYRIDINYL-2,3-DIHYDROIMIDAZO[1,2-A]PYRIMIDIN-5(1H)ONE DERIVATIVES | SANOFI-SYNTHELABO (FR) | 2003-06-04 | — | — | EP | disclosed |
| WO-2002018386-A1 | 2-PYRIDINYL-6,7,8,9-TETRAHYDROPYRIMIDO[1,2-a]PYRIMIDIN-4-ONE AND 7-PYRIDINYL-2,3-DIHYDROIMIDAZO[1,2-a]PYRIMIDIN-5(1H)ONE DERIVATI VES | SANOFI-SYNTHELABO (FR) | 2002-03-07 | — | — | WO | disclosed |
| EP-1184383-A1 | 9-[Alkyl], 9-[(heteroaryl)alkyl] and 9-[(aryl)alkyl]-2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one derivatives | SANOFI-SYNTHELABO (FR) | 2002-03-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087598-A1 | 2-pyridinyl-6,7,8,9-tetrahydropyrimido{1,2-a}pyrimidin-4-one and 7-pyridinyl-1,3-dihydoimidazo{1,2-a}pyrimidin-5(1h)one derivatives | CBR1, DPYD, SULT1E1 | GSK3B 4758/4885MAOB 919/4885ADORA2A 2005/4885 |
| US-20060014762-A1 | 2-Pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-A]pyrimidin-4-one and 7-pyridinyl-2,3-dihydoimidazo[1,2-A]pyrimidin-5(1H)one derivatives | DPYD, CBR1, TXN2 | GSK3B 4812/4885MAOB 922/4885ADORA2A 1951/4885 |
| US-20080027078-A1 | 2-PYRIDINYL-6,7,8,9-TETRAHYDROPYRIMIDO[1,2-a] PYRIMIDIN-4-ONE AND 7-PYRIDINYL-2,3-DIHYDROIMIDAZO[1,2-a] PYRIMIDIN-5(1H)ONE DERIVATIVES | PSEN2, PSEN1, GSK3A | GSK3B 4/4885MAOB 771/4885ADORA2A 503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.